Stardust Power Inc. filed an amendment to its existing At Market Issuance Sales Agreement with B. Riley Securities to update the maximum capacity of the program. The amendment allows for the potential issuance of up to an additional $8.99 million in common stock from time to time. As this filing only establishes the facility ceiling and does not disclose an actual sale or receipt of proceeds, it is classified as an administrative update to an equity facility.
Bayview Acquisition Corp deposited $50,000 into its trust account to extend the deadline for completing its initial business combination by one month. The extension moves the deadline from September 19, 2026, to October 19, 2026, and represents the fourth of six permitted monthly extensions.
Ribbon Acquisition Corp. deposited $125,000 into its trust account to extend the deadline for completing its initial business combination. The extension moves the deadline by one month from September 15, 2026, to October 15, 2026.
Graphene & Solar Technologies Limited (GSTX) announced that its common stock has been approved for uplisting to the OTCQB Venture Market, effective September 15, 2026. The company views this as a strategic step toward a potential future Nasdaq listing and a way to enhance visibility and liquidity for its U.S. silicon wafer manufacturing strategy. The filing also notes an ongoing private offering of up to $40 million in convertible notes to fund its San Diego production facility.
Medtronic plc has commenced an exchange offer to distribute up to 225,361,295 shares of MiniMed Group, Inc. common stock to its shareholders in exchange for outstanding Medtronic ordinary shares. This transaction is part of a spin-off or demerger process where Medtronic is divesting its interest in MiniMed. The filing also notes a typographical correction regarding guaranteed delivery procedures in the previously filed prospectus.
Azio AI Holdings, Inc. filed an amendment to its Certificate of Designation for Series A Non-Voting Convertible Preferred Stock to modify the definition of a 'Fundamental Transaction.' The change specifically updates the clause regarding tender or exchange offers to include transactions where more than 50% of common stock is exchanged or converted into other securities, cash, or property.
Loop Industries has formed a Strategic Alternatives Committee to evaluate options for maximizing shareholder value, including potential sales, mergers, or going-private transactions. The committee's immediate priority is securing capital and project financing for the company's planned India joint venture. This board-led process follows the recent separation of the Chairman and CEO roles.
DarkHorse Technologies Inc. (formerly Sphere 3D Corp.) completed its corporate rebrand and legal continuance from Ontario to British Columbia. In connection with the name change, the company's ticker symbol on the Nasdaq Capital Market changed from 'ANY' to 'DRK' effective September 17, 2026.
American Rebel Holdings reported a series of balance sheet and administrative updates, including the exchange of $93,000 in debt for common stock with Streeterville Capital and several promissory note conversions by 1800 Diagonal Lending. Additionally, the company amended the employment agreement for its COO Corey Lambrecht to extend his term through 2029 and launched a new marketing campaign for its light beer brand ahead of the Philadelphia Eagles' home opener.
bioAffinity Technologies announced that the Hong Kong Intellectual Property Department has granted a patent (HK40048460) for its CyPath Lung diagnostic technology. This patent, alongside a previously granted Chinese patent, strengthens the company's intellectual property position in the Asian market, which accounts for nearly two-thirds of global lung cancer cases.
StablecoinX entered into a waiver agreement with the Ethena Foundation to permanently release lock-up and vesting restrictions on ENA tokens held by the company, effective October 5, 2026. The agreement also establishes a framework for the company to sell these tokens to fund working capital and strategic requirements, subject to a right of first refusal by the Foundation.
Aquestive Therapeutics has resubmitted its New Drug Application (NDA) to the FDA for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions. The resubmission addresses a prior Complete Response Letter by including new human factors and pharmacokinetic data, notably reducing the median pouch-opening time from 17 seconds to 3 seconds. The company also filed an investor presentation from the H.C. Wainwright 28th Annual Global Investor Conference.
GlobalTech Corporation provided a status update on its planned uplisting from the OTCQB to the Nasdaq Capital Market, which remains under review. The company recently completed a 1-for-3 reverse stock split and is implementing new board committees to meet governance requirements. Management expects to potentially complete the uplisting in the fourth quarter of 2026, subject to meeting all listing standards.
NeOnc Technologies executives, including CEO Amir Heshmatpour and CMO Dr. Thomas Chen, have purchased approximately $629,000 worth of company stock in the open market following positive Phase 2a clinical results. CEO Heshmatpour specifically purchased 35,000 shares on September 15, 2026, bringing his total personal investment in the company to over $1.5 million in the past year.
Nuburu, Inc. announced that its financial statements for the three and six months ended June 30, 2026, can no longer be relied upon and will be restated. The restatement is due to a material error in the fair value calculation of a convertible note receivable from Tekne S.p.A., which resulted in an undervaluation of assets by approximately $0.76 million.
SurgePays, Inc. dismissed TAAD LLP as its independent registered public accounting firm and engaged Sadler, Gibb & Associates, LLC as its new auditor. The company noted that TAAD LLP's previous report for the fiscal year ended December 31, 2025, included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
Pasithea Therapeutics Corp. announced that its warrants (KTTAW) will expire on September 17, 2026, and will subsequently be delisted from The Nasdaq Capital Market. Any warrants not exercised prior to the expiration date will cease to be exercisable and will have no further value. The company's common stock (KTTA) will continue to trade on Nasdaq.
YHN Acquisition I Limited shareholders approved a charter amendment and trust agreement amendment to extend the company's deadline to consummate a business combination. The board now has the discretion to extend the liquidation date from September 19, 2026, to June 19, 2027, by depositing $100,000 into the trust account for each of the three possible three-month extensions.
Gaucho Group Holdings, Inc. dismissed CBIZ CPAs P.C. and engaged GuzmanGray as its new independent registered public accounting firm to audit its financial statements for the years 2024 and 2025. The company reported existing material weaknesses in internal controls over financial reporting related to segregation of duties and IT general controls. This filing is an amendment to correct the approval date and scope of the new auditor's engagement.
Alpha Pro Tech, Ltd. dismissed Tanner LLP as its independent registered public accounting firm and appointed MNP LLP for the fiscal year ending December 31, 2026. The company reported no disagreements or reportable events with the former auditor regarding accounting principles or practices.
Black Rock Petroleum Company disclosed that its President and CEO, Zoltan Nagy, was indicted on a criminal offense in the Northern District of Atlanta Division. The indictment relates to a company called Lotus Bio-Technology Development Corp., and the company noted that the allegations have not been proven in court.
Schneider National, Inc. filed an 8-K reporting the entry into and termination of material definitive agreements. Without specific document content, the filing indicates a significant corporate transaction or restructuring of contractual obligations, typically involving credit facilities or major commercial partnerships.
Allarity Therapeutics has been granted Japanese Patent No. 7917283 by the Japan Patent Office, covering its proprietary stenoparib-specific Drug Response Predictor (DRP) companion diagnostic. The patent provides intellectual property protection in Japan through 2039 for methods of predicting clinical benefit and selecting patients for stenoparib treatment. This follows similar patent protections already secured in the United States, Europe, and Australia.
Shuttle Pharmaceuticals issued approximately 3.7 million shares of common stock following the conversion of Series B-1 and B-2 Preferred Stock. Additionally, the company issued warrants to purchase 927,114 shares at $10.30 per share and pre-funded warrants for 16.9 million shares, following stockholder approval at a special meeting.
AEye, Inc. entered into an At Market Issuance Sales Agreement with A.G.P./Alliance Global Partners to establish an at-the-market (ATM) offering program for up to $50 million of common stock. Simultaneously, the company terminated its previous 2022 Common Stock Purchase Agreement with B. Riley Principal Capital II, LLC. No shares were reported sold at the time of this filing, and the company is under no obligation to sell any shares under the new agreement.
Fusemachines Inc. entered into a Securities Purchase Agreement to issue 2,138,935 shares of common stock to certain vendors and service providers. The shares are being issued at a price of $0.6103 per share to satisfy and cancel approximately $1.30 million in accrued and unpaid fees. This debt-for-equity swap allows the company to settle outstanding obligations without cash expenditure.
Pulse Biosciences entered into a new equity distribution agreement with Mizuho Securities to establish an at-the-market (ATM) offering program for up to $85 million in common stock. This new facility replaces a previous August 2026 ATM program under which the company sold approximately $68.8 million in shares. As of this filing, no shares have been sold under the new $85 million agreement.
Zeo ScientifiX, Inc. has changed its fiscal year end from October 31 to June 30, effective for the fiscal year ending June 30, 2026. The company will file a transition report on Form 10-KT for the eight-month period from November 1, 2025, through June 30, 2026.
Aligos Therapeutics entered into a first amendment to its headquarters lease in South San Francisco, extending the term from March 2027 to March 2034. The amendment sets a graduated monthly base rent starting at $4.650 per square foot and includes a ten-month rent abatement period and a one-time termination option in 2031.
Jaguar Health entered into exchange agreements to settle outstanding obligations through the issuance of common stock. The company issued 557,377 shares to Lincoln Alternative Strategies LLC to cancel a $175,016.36 promissory note and issued additional shares to Streeterville Capital, LLC in exchange for shares of Series Q Perpetual Preferred Stock.